GOSS — Gossamer Bio Inc
NASDAQ · Healthcare · Biotechnology
$0.17
-$0.00 (-0.72%)
Gossamer Bio Inc (GOSS) is a biotechnology company listed on NASDAQ. It is led by Faheem Hasnain, based in 3115 Merryfield Row, San Diego, CA, United States, 92121, with about 161 employees. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Latest reported GOSS revenue for 2025-09-30 was $13.3M. Net income was -$123.1M. Revenue was up 15.7% from 2025-06-30 to 2025-09-30. GOSS currently screens at market cap $47.0M.
Use this GOSS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GOSS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GOSS SEC filings page. Lician reads the product cache first so this HTML stays unique to Gossamer Bio Inc even when a live quote feed is slow.
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
GOSS Key Statistics
Market Cap
$46.99M
Volume
46.82M
Previous Close
$0.17
Day Range
$0.17 – $0.21
EPS
-$0.25
Revenue
$114.70M
Net Income
-$56.53M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-49.3%
Employees
161
GOSS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $114.70M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$56.53M | -$179.82M | -$229.38M | -$234.00M |
| EPS (Diluted) | -$0.25 | -$1.18 | -$2.71 | -$3.13 |
Total Assets
$315.29M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$46.07M
Operating Cash Flow
-$3.47M
Free Cash Flow
$0.00
Gossamer Bio Inc Company Information
- Co-Founder, CEO, President & Chairman
- Faheem Hasnain
- Headquarters
- 3115 Merryfield Row, San Diego, CA, United States, 92121
- Website
- www.gossamerbio.com
- Phone
- 858 684 1300
- IPO / Founded
- 2019-02-08
- Sector
- Healthcare
- Industry
- Biotechnology